Objective Effects of azithromycin combined with cefodiazine sodium on clinical symptoms and inflammatory status in patients with pulmonary infection. Methods Selected 112 cases of pulmonary infection from March 2014 to March 2016, randomly divided into observation group and control group, analysis of the improvement of clinical symptoms and inflammatory status in the two groups. Results After treatment in the observation group and the control group, the remarkable effect was 33(58.93%), 25(44.64%); the effective was 18(32.14%), 17(30.36%); the invalid was 5(8.93%), 14(25.00%); the total effective rate was 51(91.07%), 42(75.00%), there was significant difference. After treatment, there were significant differences in cough and expectoration, acute asthma, fever and lung rale disappearance between the observation group and the control group. After treatment, compared with the control group, the average of NO, SP-A and HMGB1 in the observation group decreased significantly, and the level of ChE increased significantly. After treatment, the serum levels of PAF, TNF-α, IL -6, MIP-1α, CRP and PCT decreased significantly in the observation group compared with the control group. The adverse reactions of the observation group and the control group were nausea and vomiting 2(3.57%), 1(1.79%), abdominal distention and diarrhea 1(1.79%) and 1(1.79%). Conclusion The combination of azithromycin and cefodizime sodium can improve the clinical symptoms of the patient, reduce the inflammatory state, and has good safety.

azithromycin    cefodizime sodium    pulmonary infection    inflammation